Pegunigalsidase alfa (ELFABRIO)
Enzyme replacement therapy (pegylated recombinant alpha-galactosidase A)
Pegunigalsidase alfa (ELFABRIO)
Forms and strengths
Form: TabletStrength: 2 mg/mL
References
Indication
- Pegunigalsidase alfa is used for the long-term treatment of adults with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency).
Pregnancy
- There are no available data on the use of pegunigalsidase alfa in pregnant women, and its use during pregnancy is not recommended.
- Animal studies in pregnant rabbits showed maternal toxicity and embryo-fetal toxicity, including increased pregnancy loss and reduced fetal weight, at clinically relevant doses.
- Pegunigalsidase alfa was shown to cross the placenta in pregnant rats, resulting in fetal exposure.
- Health care providers should report any pregnancy occurring during treatment to the manufacturer's pregnancy safety program.
Breastfeeding
- It is not known whether pegunigalsidase alfa passes into human breast milk, though animal studies have shown excretion into milk.
- A risk to the breastfed infant cannot be excluded, so the benefits of breastfeeding should be weighed against the mother's need for treatment.
Geriatrics
- The safety and efficacy of pegunigalsidase alfa in patients over 65 have not been established, since clinical trials did not include this age group; caution is advised when prescribing to older adults.
Pediatrics
- Pegunigalsidase alfa is not authorized for use in patients under 18 years of age, as no pediatric data are available to Health Canada.
Dosage & Administration
- The recommended dose is 1 mg/kg of actual body weight, given by intravenous infusion every other week.
- No specific dose adjustment is recommended for patients with renal or hepatic impairment.
- For the initial 4 to 6 infusions, the infusion rate is based on body weight: 50 mL/h for patients under 70 kg, 83 mL/h for 70-100 kg, and 167 mL/h for patients over 100 kg; the rate may be increased in later infusions if tolerated.
- Premedication with antihistamines, antipyretics, and/or corticosteroids may be considered before the first several infusions, particularly in patients switching from another enzyme replacement therapy or with a prior hypersensitivity reaction.
- For a mild to moderate hypersensitivity or infusion-associated reaction, the infusion may be temporarily paused for 15 to 30 minutes and restarted at a slower rate; for a severe reaction, the infusion must be stopped immediately.
- If symptoms subside after slowing or holding the infusion, it may be resumed at 25% to 50% of the rate at which the reaction occurred, then gradually increased if tolerated.
- Treatment must be managed by a healthcare professional experienced in treating Fabry disease, with administration supervised at home, in clinic, or in hospital.
- Vials should sit at room temperature for 15 to 30 minutes before use, and shaking or agitating the vial must be avoided to prevent foaming; an external heat source should never be used to warm it.
- Other medications should not be infused through the same intravenous line as pegunigalsidase alfa, and an in-line 0.2 micron low protein-binding filter should be used for administration.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- There is no clinical trial experience with pegunigalsidase alfa overdose, so a specific overdose toxidrome has not been characterized.
- Management of overdose is immediate supportive medical care with close observation of the patient's clinical status.
Common side effects
- Nasopharyngitis (common cold-type symptoms) is very common.
- Fatigue is very common.
- Headache is very common.
- Back pain is very common.
- Cough is very common.
- Diarrhea is very common.
- Pain in the arms or legs is very common.
- Nausea is very common.
- Upper respiratory tract infection is very common.
- Fever (pyrexia) is very common.
- Sinusitis is very common.
- Vomiting is common.
- Chills are common.
- Itching (pruritus) is common.
- Dizziness is common.
- Numbness or tingling (paresthesia) is common.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Severe hypersensitivity reactions, including anaphylaxis, have occurred, most often during the first infusion.
- Infusion-associated reactions, including hypersensitivity, itching, nausea, dizziness, chills, and muscle pain, can occur during or shortly after an infusion.
- A serious case of membranoproliferative glomerulonephritis (kidney inflammation from immune complex deposits) has been reported, causing a decline in kidney function that did not fully return to baseline after stopping treatment.
- Antibodies against the drug can develop, particularly in patients switching from another enzyme replacement therapy, and may increase the risk of hypersensitivity and infusion reactions.
- Seek urgent medical attention for signs of a severe allergic reaction, such as difficulty breathing, wheezing, swelling of the face or throat, or a sudden drop in blood pressure during or after an infusion.
Use with caution
- Use with caution in patients previously treated with another enzyme replacement therapy, since pre-existing antibodies may increase the risk of hypersensitivity and infusion-associated reactions.
- Use with caution in patients with compromised cardiac function, who may be at higher risk of complications from infusion-associated reactions.
- Use with caution and consider monitoring kidney function (serum creatinine and urine protein-to-creatinine ratio) if there is clinical concern about declining renal function.
- Use with caution when driving or operating machinery, since dizziness and vertigo have been reported.
- Use with caution and consider monitoring clinical or laboratory response (such as plasma lyso-Gb3 levels) when switching a patient from another enzyme replacement therapy to pegunigalsidase alfa.
- Use with caution regarding fertility counseling, since the effects of pegunigalsidase alfa on human fertility have not been studied.
- Appropriate medical support, including cardiopulmonary resuscitation equipment, should be readily available during every infusion given the risk of anaphylaxis.
Contraindications
- Contraindicated in patients with known hypersensitivity to pegunigalsidase alfa or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.
Drug interactions
- No formal drug interaction studies have been conducted with pegunigalsidase alfa.
- Interactions with other drugs have not been established.
- Interactions with behavioural factors such as smoking, cannabis use, or alcohol consumption have not been studied.
Food interactions
- No food interactions have been established for this intravenous infusion.
Time of administration
- Administered by intravenous infusion every other week; timing is not tied to meals or time of day, though infusions should be scheduled with adequate time for pre-infusion preparation and post-infusion monitoring.
Storage
- Store vials in the refrigerator at 2°C to 8°C. Do not freeze.
- Once diluted for infusion, the solution is stable for up to 24 hours refrigerated followed by up to 8 hours at room temperature, or up to 72 hours total if stored consistently at either condition; do not freeze or shake the diluted solution.
Patient take-away
- Pegunigalsidase alfa is a long-term enzyme replacement infusion given every other week to treat Fabry disease.
- Because severe allergic reactions, including anaphylaxis, can occur, infusions are given under medical supervision with monitoring during and after each infusion.
- Common effects include cold-like symptoms, fatigue, headache, and joint or limb pain, especially around the time of infusion.
- Tell your healthcare professional right away about any signs of a severe allergic reaction, or any changes in urine output or unusual swelling that could suggest a kidney problem.